Tubular Markers in Response to Saxagliptin Therapy
Status:
Completed
Trial end date:
2020-04-01
Target enrollment:
Participant gender:
Summary
the study aims to investigate whether treatment with saxagliptin would induce beneficial
changes in renal NGAL and L-FABP biomarkers and if they would be used as a tool to identify
patients' categories with a particular renal response to DPP-4inhibition. Secondly, to find
an association between NGAL and L-FABP, and the relevant renal parameters for both baseline
values and rate of changes across defined time points.